【摘要】 目的 观察匹伐他汀治疗糖尿病合并高胆固醇血症的疗效和不良反应。方法 选取2019年1月—2020年12月在玉林市第一人民医院治疗的糖尿病合并高胆固醇血症患者80例，按随机数字表法分为匹伐他汀组和瑞舒伐他汀组，各40例，分别给予匹伐他汀和瑞舒伐他汀治疗，2组均治疗3个月。比较2组治疗效果，治疗前后血糖指标[空腹血糖（FPG）、餐后2 h血糖（2 hPG）、糖化血红蛋白(HbA_1c)]、血脂指标[总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）]、炎性因子[超敏C反应蛋白（hs-CRP）、白介素-18（IL-18）、肿瘤坏死因子-α（TNF-α）]及药物不良反应。结果 匹伐他汀组总有效率为95.00%,高于瑞舒伐他汀组的80.00%（χ²=4.114,P=0.043）。治疗3个月后，瑞舒伐他汀组FPG、2 hPG、HbA_1c水平无显著变化（P>0.05）,匹伐他汀组FPG、2 hPG、HbA_1c水平低于治疗前和同期瑞舒伐他汀组（P<0.01）;2组TC、TG、LDL-C水平低于治疗前，且匹伐他汀组TC水平低于瑞舒伐他汀组（P<0.01）,2组TG、LDL-C水平比较差异无统计学意义（P>0.05）;2组hs-CRP、IL-18、TNF-α水平均低于治疗前，且匹伐他汀组低于瑞舒伐他汀组（P<0.05或P<0.01）。匹伐他汀组与瑞舒伐他汀组药物不良反应总发生率比较差异无统计学意义（2.50%vs. 12.50%,χ²=2.883,P=0.090）。结论 匹伐他汀治疗糖尿病合并高胆固醇血症的疗效优于瑞舒伐他汀，能有效调节患者血糖、血脂水平，降低炎性反应，且不良反应较少。更多还原

【Abstract】 Objective To observe the efficacy and adverse reactions of pitavastatin in the treatment of diabetes mellitus combined with hypercholesterolemia. Methods Eighty patients with diabetes mellitus combined with hypercholesterolemia treated in the First People′s Hospital of Yulin from January 2019 to December 2020 were selected and divided into pitavastatin group and rosuvastatin group according to the method of randomized numerical table, 40 cases in each group, pitavastatin and rosuvastatin were given respectively, and both groups were treated for 3 months. The treatment effect, blood glucose index(FPG,2 hPG,HbA_1c), blood lipid indexes（TC, TG, LDL-C）, inflammatory factors（hs-CRP, IL-18,TNF-α） before and after treatment, and adverse drug reaction were compared between the two groups. Results The total effective rate was 95.00% in pitavastatin group, which was higher than 80.00% in rosuvastatin group（χ²=4.114, P=0.043）. After 3 months of treatment, there were no significant changes in FPG, 2 hPG, and HbA_1c levels in rosuvastatin group（P>0.05）, and the levels of FPG, 2 hPG, and HbA_1c in the pitavastatin group were lower than those before treatment and in the same period in the rosuvastatin group（P<0.01）; The levels of TC, TG, and LDL-C in the two groups were lower than before treatment, and the level of TC in pitavastatin group was lower than that in rosuvastatin group（P<0.01）, and there was no statistically significant difference in the comparison of TG and LDL-C levels between the two groups（P>0.05）; The levels of hs-CRP, IL-18, and TNF-α in the two groups were lower than those before treatment, and the pitavastatin group were lower than the rosuvastatin group（P<0.05 or P<0.01）. The difference in the overall incidence of adverse drug reactions between the pitavastatin group and the rosuvastatin group was not statistically significant（2.50% vs. 12.50%, χ²=2.883, P=0.090）. Conclusion Pravastatin is effective in the treatment of diabetes mellitus with hypercholesterolemia, is better than rosuvastatin in improving blood glucose and blood lipids, and has less adverse reactions.更多还原